AHARTT

Catherine Martin, MD

Biography

Catherine Martin received her medical degree at the University of Kentucky College of Medicine. She also did her residency and her fellowship at the University of Kentucky. Dr. Martin is the Division Director for Child & Adolescent Psychiatrist at the University of Kentucky. Her interests include: Biological Markers for High-Risk Behaviors in Adolescents; Substance Abuse; ADHD; Adolescent Smoking and Smoking Interventions.

Affiliation

  • Dr. Laurie L. Humphries Endowed Chair in Child Psychiatry
    Division Director of Child and Adolescent Psychiatry
    Professor of Psychiatry
    Department of Psychiatry
    College of Medicine
    University of Kentucky
    Lexington, KY
Activities Involving Catherine Martin
»

Kristin Dawson, MD

Biography

Kristin Dawson earned her medical degree at the University of Kentucky, College of Medicine, in Lexington. Dr. Dawson completed a psychiatry residency at the University of Utah, School of Medicine in Salt Lake City before returning to the University of Kentucky to complete training in child and adolescent psychiatry. She is board certified by the American Board of Psychiatry & Neurology in Psychiatry as well as Child and Adolescent Psychiatry.

Affiliation

  • Assistant Professor of Psychiatry
    Associate Program Director, Child & Adolescent Psychiatry
    College of Medicine
    University of Kentucky
    Lexington, Kentucky
Activities Involving Kristin Dawson
»

Ginny Sprang, PhD

Biography

Ginny Sprang, PhD, is the Buckhorn Professor of Child Welfare and Children’s Mental Health at the University of Kentucky. She is a Professor with a joint appointment in the College of Social Work and the College of Medicine Department of Psychiatry. Dr. Sprang served as a Visiting Professor in the Department of Psychiatry at the University of Colorado Irving Harris Program in Child Development and Infant Mental Health during her sabbatical. Dr. Sprang is a Principal Investigator and Executive Director of the Center on Trauma and Children, a center whose mission is dedicated to the enhancement of the health and well-being of children and their families through research, service, and dissemination of information about child trauma. Dr. Sprang serves as Principal Investigator for many of CTAC’s state and federal grants and contracts. She served as a member of the National Steering Committee for the National Child Traumatic Stress Network (NCTSN), is the current Co-Chair of the Secondary Traumatic Stress Committee for the NCTSN, and is the Chair of the Terrorism and Disaster Special Interest Group of the International Society for Traumatic Stress Studies. Her scholarship focuses on the clinical, forensic, and empirical aspects of traumatic stress and the efficacy and effectiveness of treatments to address the biopsychosocial impact of violence against children. Dr. Sprang has published extensively in the leading journals focusing on trauma, maltreatment, and treatment efficacy in adults and children.

Affiliations

  • Executive Director
    University of Kentucky Center on Trauma and Children
    Lexington, Kentucky
  • Professor
    University of Kentucky College of Social Work
    University of Kentucky College of Medicine
    Department of Psychiatry
    Lexington, Kentucky
Activities Involving Ginny Sprang
»

Daniel Wermeling, PharmD, FCCP, FASHP

Biography

Dr. Wermeling earend a PharmD degree from the University of Kentucky College of Pharmacy. He completed a 2-year clinical pharmacy residency at the UK Chandler Medical Center in Lexington, Kentucky. He completed a drug development fellowship under Dr. Thomas Foster at the University Of Kentucky College Of Pharmacy. After a brief stint in pharmaceutical industry, Dr. Wermeling became an Assistant Research Professor and Director of the University of Kentucky College of Pharmacy Drug Product Evaluation Unit, and, Director of the UK Hospital Department of Pharmacy Investigational Drug Service. Since joining the faculty, he has practiced at the University of Kentucky Medical Center and taught courses in analgesic therapeutics, drug delivery, and clinical research methods. He has led multidisciplinary clinical research programs and projects with investigational drugs. He was also co-founder of the Medical Center’s clinical trials office. Dr. Wermeling has an active interest in pharmaceutical development and has advanced university intellectual property from non-clinical status to clinical development protocols by filing Investigational New Drug applications with FDA. Dr. Wermeling has considerable pharmaceutical regulatory experience. Dr. Wermeling has an extensive clinical research and drug development experience. Although he has studied a wide variety of therapeutic entities, a significant portion of his experience is with opiate pain medications, benzodiazepines, analgesic medications and drug delivery systems. Dr. Wermeling has published widely in this area. He is also an expert in nasal drug delivery biopharmaceutics, drug delivery and clinical research. He has co-founded a company, Intranasal Therapeutics, Inc., that was a spin-out from the College of Pharmacy. The research resulted in six patent submissions of which two have been issued. His research has served as a basis for training students, residents, and graduate students in clinical research methodologies. He instructs 2nd year professional pharmacy students in the treatment of pain and the use of analgesics. Dr. Wermeling’s latest research is to examine whether medications used chronically for the treatment of alcoholism can be administered acutely to treat the craving and urges that lead to relapse. He has designed intranasal medication and delivery systems that permit rapid absorption and systemic availability. Moreover, with a team of scientists from the Magnetic Resonance Imaging and Spectroscopy Center (MRISC), Departments of Behavioral Medicine and Psychiatry, and financial and operational support from the Clinical Research and Development Operations Center (CR-DOC), he has developed a novel test system utilizing functional MRI as a tool to study the rapidly absorbed medication’s effects on neuronal activation within regions of the brain recognized to sub-serve craving and urges to drink. Subsequent research will examine if the rapidly absorbed medication systems can affect drinking behavior. His background includes studying the clinical pharmacology of analgesic delivery systems. He is responsible for the College of Pharmacy and the Interdisciplinary Pain Management Training Programs at UK. His current research interest is in the nasal delivery of naloxone as a needle-free delivery method of the opioid antidote. He is developing a unit-dose naloxone nasal spray product, currently NIDA funded, and in FDA development.

Affiliation

  • Professor, Pharmacy Practice and Science
    University of Kentucky College of Pharmacy
    Owner/CEO, AntiOp, Inc.
    Lexington, Kentucky
Activities Involving Daniel Wermeling
»